-0.67   (-5.24%)
Volume (24h) Market Cap. Day Range 52w Range
1.75M 432.90M 11.77 - 13.29 1.63 - 13.68
Jan-04-21 08:30AM Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development OfficerGlobeNewswire
Dec-22-20 07:31AM Cassava Sciences' (SAVA) Shares March Higher, Can It Continue?Zacks
Dec-07-20 08:19AM Is SAVA A Good Stock To Buy Now?Insider Monkey
Nov-27-20 08:30AM USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’GlobeNewswire
Nov-19-20 10:08AM Pacira (PCRX) Gets European Commission Approval for ExparelZacks
Nov-18-20 09:36AM 3 Best Biotech Stocks to Buy in NovemberMotley Fool
Nov-16-20 10:06AM Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EUZacks
Nov-13-20 09:42AM Zoetis (ZTS) Librela Gets Marketing Authorization in EuropeZacks
09:08AM Cassava Sciences Announces Pricing of $75 Million Public Offering of Common StockGlobeNewswire
Nov-13-20 08:07AM Why Cassava Sciences Stock Is Retreating TodayMotley Fool
Nov-12-20 04:48AM Cassava Sciences Announces Proposed Public Offering of Common StockGlobeNewswire
Nov-09-20 08:15AM Cassava Sciences Reports Third Quarter 2020 Financial ResultsGlobeNewswire
Nov-04-20 08:15AM Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’s DiseaseGlobeNewswire
Oct-26-20 09:19AM What's in the Cards for Cassava (SAVA) This Earnings Season?Zacks
Oct-23-20 10:15AM Why Cassava Sciences Is Bolting Higher TodayMotley Fool
Oct-12-20 03:29AM We're Not Worried About Cassava Sciences' (NASDAQ:SAVA) Cash BurnSimply Wall St.
Oct-07-20 09:35AM Why Cassava Sciences Stock Crushed It in SeptemberMotley Fool
07:05AM Moving Average Crossover Alert: Cassava SciencesZacks
Sep-30-20 08:30AM Cassava Sciences’ Phase 2b Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2020GlobeNewswire
07:55AM 4 Small Drug Stocks to Look Out For Amid Coronavirus UncertaintyZacks
Sep-28-20 07:44AM Cassava Sciences (SAVA) Stock Is up 255% This Month. How Much Higher Can It Go?TipRanks
07:38AM Cassava Sciences' Shares March Higher, Can It Continue?Zacks
Sep-27-20 08:09AM Is Cassava Sciences Stock a Buy?Motley Fool
Sep-22-20 10:04AM Why Cassava Sciences Stock Is Bolting Higher TodayMotley Fool
Sep-21-20 01:34AM Trading My First Red Week After Six Months Of GreenBenzinga
Sep-20-20 06:53AM Does Cassava Sciences Have the Alzheimer's Disease Drug We've Been Waiting For?Motley Fool
Sep-16-20 02:03AM This Biotech Stock Moves One Step Closer to an Alzheimer’s Drug; Analyst Says ‘Buy’TipRanks
Sep-14-20 12:44PM Cassava Sciences rockets on heavy volume after Alzheimer's drug trial results prompts analyst upgradeMarketWatch
07:15AM Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer’s DiseaseGlobeNewswire
Sep-11-20 04:01AM Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ETGlobeNewswire
Sep-09-20 08:15AM Cassava Sciences to Present at H.C. Wainwright’s 22nd Annual Global Investment ConferenceGlobeNewswire
Sep-03-20 08:15AM Cassava Sciences Announces New Patent GrantGlobeNewswire
Aug-24-20 08:15AM Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name ‘sumifilam’ by USANGlobeNewswire
Aug-12-20 08:15AM Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business ReviewGlobeNewswire
Jul-14-20 08:44AM Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%Zacks
Jul-09-20 04:01AM Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific ConferenceGlobeNewswire
Jun-16-20 08:15AM Cassava Sciences Added to Russell Indexes and Provides Phase 2b Study UpdateGlobeNewswire
Jun-10-20 04:33AM Hedge Funds Cautiously Watching Cassava Sciences, Inc. (SAVA)Insider Monkey
Jun-03-20 08:15AM Cassava Sciences Announces Presentation at the Jefferies Virtual Healthcare Conference and Provides Updates Regarding Phase 2b Study of PTI-125GlobeNewswire
May-19-20 07:57AM Cassava Sciences (SAVA): Let’s Shed Some Light on That CrashTipRanks
09:46AM Cassava Sciences (SAVA) in Focus: Stock Moves 8.5% HigherZacks
May-15-20 02:05AM Cassava Sciences Alzheimer's Drug Candidate Misses Trial EndpointTheStreet.com
11:31AM Cassava stock falls on failed Alzheimer's studyMarketWatch
May-15-20 08:15AM Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary EndpointGlobeNewswire
May-06-20 08:48AM Add Value to Your Portfolio With 5 High Earnings Yield PicksZacks
08:15AM Cassava Sciences Reports First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire
Apr-24-20 10:03AM Company News for Apr 24, 2020Zacks
Apr-23-20 08:15AM Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of HealthGlobeNewswire
Apr-13-20 01:25AM We're Excited To See How Cassava Sciences (NASDAQ:SAVA) Uses Its Cash Hoard To GrowSimply Wall St.
Mar-26-20 08:15AM Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020GlobeNewswire
Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Cap:    |  Volume (24h):